Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $11.3 million.

  • ARS Pharmaceuticals' Accumulated Expenses changed N/A to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Accumulated Expenses stood at $11.3 million.
  • ARS Pharmaceuticals' 5-year Accumulated Expenses high stood at $12.8 million for Q2 2021, and its period low was $2.3 million during Q4 2024.
  • Its 4-year average for Accumulated Expenses is $8.8 million, with a median of $11.1 million in 2022.
  • Examining YoY changes over the last 5 years, ARS Pharmaceuticals' Accumulated Expenses showed a top increase of 9061.91% in 2022 and a maximum decrease of 7089.42% in 2022.
  • Over the past 4 years, ARS Pharmaceuticals' Accumulated Expenses (Quarter) stood at $11.7 million in 2021, then tumbled by 68.88% to $3.6 million in 2022, then plummeted by 37.16% to $2.3 million in 2024, then surged by 391.54% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in Q3 2025, $2.3 million for Q4 2024, and $3.6 million during Q3 2022.